Zacks Research cut shares of GeneDx (NASDAQ:WGS – Free Report) from a strong-buy rating to a hold rating in a report released on Thursday,Zacks.com reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a research report on Saturday, September 27th. Wall Street Zen raised shares of GeneDx from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. T. Rowe Price Investment Management Inc. bought a new position in shares of GeneDx during the 1st quarter worth about $44,614,000. GeneDx Company Profile(Get Free Report)GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services.